Press Releases Latest May 09, 2024 Theratechnologies Reports on its Annual Meeting of Shareholders Press Releases Year None202420232022202120202019201820172016201520142013 Sep 05, 2023 Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights Aug 30, 2023 Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide Jul 31, 2023 Theratechnologies Completes 1-for-4 Reverse Stock Split Jul 28, 2023 Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management Jul 21, 2023 Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn Jul 20, 2023 Theratechnologies Announces 1-for-4 Reverse Stock Split Jul 12, 2023 Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 41 - 50 of 362
Aug 30, 2023 Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
Jul 28, 2023 Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
Jul 21, 2023 Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial